3 results about "Elevated serum" patented technology

The invention discloses construction and application of a Primrose syndrome non-human animal model, and belongs to the technical field of animal models and disease research. According to the invention, through a CRISPR / Cas9 technology, a codon CAC for coding 596th histidine in a No.14 exon of a mouse Zbtb20 gene is subjected to site-directed mutagenesis into CGC for coding arginine, and a hybrid mouse model for simulating pathogenic point mutation (p.H596R) of human Primrose syndrome is constructed. The model can stably reproduce key clinical phenotypes of the Primrose syndrome, including overgrowth after adult, serum IGF-1 rise, memory dysfunction and anxiety behaviors, and shows abnormal hippocampal neuronal development and synaptic transfer related pathways and the like. The invention provides an important experimental tool for deeply revealing the pathological mechanism of Primrose syndrome, developing drug screening and treatment intervention research and the like.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

The present invention relates to compositions comprising microorganisms for use in the reduction of blood urate concentration. These compositions can be used for the therapeutic and the preventive treatment of subjects at risk or suffering from elevated blood urate levels. The compositions can be pharmaceutical compositions or nutraceutical composition 5 that are used for treatment and prevention of urate and hyperuricemia associated diseases such as cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease, gout, insulin resistance, hypertension, dyslipidaemia, renal insufficiency, obesity, pre-diabetes and diabetes.